Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label randomized comparison of nipocalimab versus efgartigimod in generalized myasthenia gravis with a switch-to-nipocalimab cohort
MOH_2025-09-03_014312Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nipocalimab and efgartigimod alfa in myasthenia gravis (MG) (3 arms), sponsored by Janssen Pharmaceutical. Started Aug 2025; status: recruiting.
02
Drugs
nipocalimabefgartigimod alfa
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on MOH_2025-09-03_014312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-09-03_014312.